(Q49339093)

20 February 2018

title

The tumour glyco-code as a novel immune checkpoint for immunotherapy. (English)

1 reference

20 February 2018

1 reference

3

Yvette van Kooyk

1 reference

20 February 2018

author name string

Ernesto RodrÍguez

series ordinal

1

1 reference

20 February 2018

Sjoerd T T Schetters

series ordinal

2

1 reference

20 February 2018

publication date

5 February 2018

1 reference

20 February 2018

Nature Reviews Immunology

published in

1 reference

20 February 2018

Cancer immunoediting: from immunosurveillance to tumor escape

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

CANCER IMMUNOLOGY. The "cancer immunogram".

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Oncology meets immunology: the cancer-immunity cycle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

The future of immune checkpoint therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Since there are PAMPs and DAMPs, there must be SAMPs? Glycan “self-associated molecular patterns” dampen innate immunity, but pathogens can mimic them

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Protein-glycan interactions in the control of innate and adaptive immune responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Turning-Off Signaling by Siglecs, Selectins, and Galectins: Chemical Inhibition of Glycan-Dependent Interactions in Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Glycosylation in cancer: mechanisms and clinical implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Hypoxia induces adhesion molecules on cancer cells: A missing link between Warburg effect and induction of selectin-ligand carbohydrates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Immature truncated O-glycophenotype of cancer directly induces oncogenic features

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Protein glycosylation: chaperone mutation in Tn syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Initiation of GalNAc-type O-glycosylation in the endoplasmic reticulum promotes cancer cell invasiveness.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Organelle Specific O-Glycosylation Drives MMP14 Activation, Tumor Growth, and Metastasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Dendritic cells recognize tumor-specific glycosylation of carcinoembryonic antigen on colorectal cancer cells through dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Fucose-based PAMPs prime dendritic cells for follicular T helper cell polarization via DC-SIGN-dependent IL-27 production

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

CNS myelin induces regulatory functions of DC-SIGN-expressing, antigen-presenting cells via cognate interaction with MOG

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

MGL signaling augments TLR2-mediated responses for enhanced IL-10 and TNF-α secretion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Regulation of effector T cells by antigen-presenting cells via interaction of the C-type lectin MGL with CD45.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Siglec-mediated regulation of immune cell function in disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Tumor sialylation impedes T cell mediated anti-tumor responses while promoting tumor associated-regulatory T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Sialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and de novo induction of regulatory T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Sialyl-tn in cancer: (how) did we miss the target?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Sialyl Tn-expressing bladder cancer cells induce a tolerogenic phenotype in innate and adaptive immune cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Galectins: emerging regulatory checkpoints linking tumor immunity and angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Identification of Glycopeptides as Posttranslationally Modified Neoantigens in Leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Altered N-Linked Glycosylation in Follicular Lymphoma and Chronic Lymphocytic Leukemia: Involvement in Pathogenesis and Potential Therapeutic Targeting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Mucins in pancreatic cancer and its microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Glycosylation and cancer: moving glycomics to the forefront

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Recent Advances in the Mass Spectrometry Methods for Glycomics and Cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

MALDI Mass Spectrometry Imaging of N-Linked Glycans in Cancer Tissues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Native glycan fragments detected by MALDI-FT-ICR mass spectrometry imaging impact gastric cancer biology and patient outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Comparative glycoproteomics of stem cells identifies new players in ricin toxicity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

The Haystack Is Full of Needles: Technology Rescues Sugars!

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Aberrant PSA glycosylation--a sweet predictor of prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

CA72-4 combined with CEA, CA125 and CAl9-9 improves the sensitivity for the early diagnosis of gastric cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Probing the O-glycoproteome of gastric cancer cell lines for biomarker discovery.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Role of lectin microarrays in cancer diagnosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Regulation of O-glycosylation through Golgi-to-ER relocation of initiation enzymes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Glycosyltransferase Gene Expression Profiles Classify Cancer Types and Propose Prognostic Subtypes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

A Systems Biology Approach Identifies FUT8 as a Driver of Melanoma Metastasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Glycans in cancer and inflammation--potential for therapeutics and diagnostics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Precision glycocalyx editing as a strategy for cancer immunotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Targeting aberrant sialylation in cancer cells using a fluorinated sialic acid analog impairs adhesion, migration, and in vivo tumor growth.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

The Immunoregulatory Roles of Antibody Glycosylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Antigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Elements of cancer immunity and the cancer-immune set point

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Databases and Associated Tools for Glycomics and Glycoproteomics.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Translational value of mouse models in oncology drug development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Preclinical mouse cancer models: a maze of opportunities and challenges

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

The physiological role of DC-SIGN: a tale of mice and men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Evolution of fucosyltransferase genes in vertebrates.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Colloquium paper: uniquely human evolution of sialic acid genetics and biology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

Proteomics. Tissue-based map of the human proteome

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRI.2018.3

31 March 2020

https://api.crossref.org/works/10.1038%2FNRI.2018.3

inferred from DOI database lookup

7 January 2021

based on heuristic

Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2018.3

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRI.2018.3

1 reference

20 February 2018

1 reference

20 February 2018